ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT04620330

Public ClinicalTrials.gov record NCT04620330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)

Study identification

NCT ID
NCT04620330
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Verastem, Inc.
Industry
Enrollment
90 participants

Conditions and interventions

Interventions

  • avutometinib (VS-6766) Drug
  • avutometinib (VS-6766) and Defactinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 30, 2020
Primary completion
Aug 28, 2023
Completion
Dec 11, 2023
Last update posted
Jan 11, 2024

2020 – 2023

United States locations

U.S. sites
28
U.S. states
19
U.S. cities
27
Facility City State ZIP Site status
City of Hope Duarte California 91010
University of Colorado Hospital Aurora Colorado 80045
Rocky Mountain Cancer Centers Lone Tree Colorado 80124
Georgetown University Medical Center Washington D.C. District of Columbia 20007
Florida Cancer Specialists Fort Myers Florida 33908
Florida Cancer Specialists St. Petersburg Florida 33705
Emory University School of Medicine Atlanta Georgia 30322
Northwestern University Chicago Illinois 60611
University of Chicago Medical Center-Duchossois Center for Advanced Medicine Chicago Illinois 60637
Illinois Cancer Specialists Niles Illinois 60714
Hematology/Oncology Clinic, LLP Baton Rouge Louisiana 70809
Maryland Oncology Hematology P.A Columbia Maryland 21044
Dana Farber Cancer Institute Boston Massachusetts 02215
Henry Ford Cancer Institute/Henry Ford Health System Detroit Michigan 48202
Washington University School of Medicine St Louis Missouri 63110
Hackensack University Medical Center Hackensack New Jersey 07601
Northwell Health-Monter Cancer Center Lake Success New York 11042
Zangmeister Cancer Center Columbus Ohio 43219
Northwest Cancer Specialists, P.C. Portland Oregon 97213
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Univ. of Pittsburgh Med Center Pittsburgh Pennsylvania 15232
Chattanooga Oncology Hematology Assoc. Chattanooga Tennessee 037404
Tennessee Oncology Nashville Tennessee 37203
Texas Oncology Dallas Texas 75246
Texas Oncology Ft Worth Cancer Center Fort Worth Texas 76104
Texas Oncology Grapevine Texas 76051
MD Anderson Cancer Center Houston Texas 77030
Virginia Cancer Specialists, PC Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04620330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 11, 2024 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04620330 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →